Oaktree Acquisition Corp III Life Sciences
OACC
51 hedge funds and large institutions have $181M invested in Oaktree Acquisition Corp III Life Sciences in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 2 closing their positions.
106% more capital inflows, than outflows
Capital inflows: $16.1M | Capital outflows: $7.8M
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0.27% more ownership
Funds ownership: 85.44% → 85.72% (+0.27%)
0% more funds holding
Funds holding: 51 → 51 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.82M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.76M |
| 3 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$1.22M |
| 4 |
Fort Baker Capital Management
Larkspur,
California
|
+$1.12M |
| 5 |
DAM
Decagon Asset Management
London,
United Kingdom
|
+$947K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$5.4M |
| 2 |
Shaolin Capital Management
Miami,
Florida
|
-$1.22M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$747K |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
-$223K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$109K |
OACC Hedge Fund Activity: Q2 2026 in Review
51 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Oaktree Acquisition Corp III Life Sciences (OACC) for Q2 2026, worth a combined $181M — up 1.5% from $179M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new OACC positions and 2 closed out — a net gain of 1 holder — while 12 added to existing stakes and 6 trimmed.
The largest buyer was K2 Principal Fund, adding an estimated $1.82M. The largest seller was HighTower Advisors, exiting entirely with an estimated $5.4M sold.
- 51 institutional investors held Oaktree Acquisition Corp III Life Sciences (OACC) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $181M of Oaktree Acquisition Corp III Life Sciences stock for Q2 2026, up 1.5% quarter-over-quarter.
- 3 funds opened new Oaktree Acquisition Corp III Life Sciences positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest Oaktree Acquisition Corp III Life Sciences buyer in Q2 2026 was K2 Principal Fund, an estimated $1.82M added.
- The largest Oaktree Acquisition Corp III Life Sciences seller in Q2 2026 was HighTower Advisors, an estimated $5.4M sold.
Based on aggregated 13F filings for Q2 2026.